Owlet, Inc. (OWLT): Nasdaq/NYSE listing notice — Owlet receives FDA clearance for BabySat pulse-ox; NYSE commences warrant delisting

Owlet, Inc.

FDA cleared BabySat, first medical pulse-ox device with wire-free sock design; US launch expected later in 2023.
NYSE halted trading in Owlet warrants (OWLT.WS) due to low price; moves to delist citing 'abnormally low' price levels.
Company will not appeal warrant delisting; common stock (OWLT) trading on NYSE unaffected.

item 3.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Owlet, Inc. received a nyse delisting notice notice regarding other (rules 802.01D).

Exchange: nyse
Notice: delisting notice
Rules: 802.01D

Exact text from the filing

Warrants. On June 16, 2023, the NYSE provided written notice to the Company and publicly announced that NYSE Regulation has determined to commence proceedings to delist the Warrants and that the Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. To effect the delisting, the NYSE will apply to the Securities and Exchange Commission to delist the Warrants pending completion of applicable procedures. The Company does not intend to appeal the NYSE’s determination. Trading in the Company’s Class A commo

View on SEC.gov

Browse all listing & compliance notices →

Owlet, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-023003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.